Don't know where to start with this, but I'd say somewhere around; "If I were a patient, even if an existing drug were efficacious in 90% of the population, I'd still prefer to be given a drug that's efficacious in 95% of the population"
There are some other concerns with sofosbuvir as well , such as (price notwithstanding - google it!) the necessity to use peginterferon as an adjunct in many cases, etc - I've even seen a paper referring to sofosbuvir as a short-term solution.
BLT Price at posting:
$2.28 Sentiment: LT Buy Disclosure: Held